- $1.12bn
- $550.98m
- $168.34m
- 62
- 29
- 54
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.68 | ||
| Price to Tang. Book | 1.73 | ||
| Price to Free Cashflow | 17.59 | ||
| Price to Sales | 6.67 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.97% | ||
| Return on Equity | -18.06% | ||
| Operating Margin | -82.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 156.7 | 122.69 | 275.11 | 164.58 | 168.34 | 98.67 | 147.58 | 32.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Directors
- Bassil Dahiyat PRE (50)
- John Kuch CFO (61)
- John Desjarlais SVP (56)
- Allen Yang SVP (53)
- Celia Eckert VPR (49)
- Jeremy Grunstein VPR
- Eric Kowack VPR
- Kirk Rosemark VPR (49)
- Julie Casciani OTH
- A. Bruce Montgomery LED (67)
- Ellen Feigal IND (67)
- Kevin Gorman IND (62)
- Kurt Gustafson IND (53)
- Yujiro Hata IND (47)
- Richard Ranieri IND (68)
- Dagmar Rosa - Bjorkeson IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 8th, 2004
- Public Since
- December 3rd, 2013
- No. of Shareholders
- 170
- No. of Employees
- 280
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 61,120,272
- Address
- 465 N. HALSTEAD ST., SUITE 200, PASADENA, 91107
- Web
- https://xencor.com/
- Phone
- +1 6263055900
- Auditors
- RSM US LLP
Upcoming Events for XNCR
Q2 2024 Xencor Inc Earnings Release
Similar to XNCR
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Xencor share price?
As of Today at 19:24 UTC, shares in Xencor are trading at $18.38. This share price information is delayed by 15 minutes.
How has the Xencor share price performed this year?
Shares in Xencor last closed at $18.38 and the price had moved by -35.17% over the past 365 days. In terms of relative price strength the Xencor share price has underperformed the S&P500 Index by -46.05% over the past year.
What are the analyst and broker recommendations for Xencor?
The overall consensus recommendation for Xencor is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Xencor dividend yield?
Xencor does not currently pay a dividend.
Does Xencor pay a dividend?
Xencor does not currently pay a dividend.
When does Xencor next pay dividends?
Xencor does not currently pay a dividend.
How do I buy Xencor shares?
To buy shares in Xencor you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Xencor?
As of the previous close price of $18.38, shares in Xencor had a market capitalisation of $1.12bn.
Where are Xencor shares listed?
Here are the trading details for Xencor:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: XNCR
What kind of share is Xencor?
Based on an overall assessment of its quality, value and momentum Xencor is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Xencor share price forecast for 2024?
The analyst consensus target price for shares in Xencor is $36.58. That is 99.02% above the last closing price of $18.38.
Analysts covering Xencor currently have a consensus Earnings Per Share (EPS) forecast of -$3.33 for the next financial year.
What is the trend in the Xencor share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xencor. Over the past six months, its share price has underperformed the S&P500 Index by -14.22%.
As of the last closing price of $18.38, shares in Xencor were trading -12.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Xencor PE Ratio?
The Xencor PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Xencor?
Xencor's management team is headed by:
- Bassil Dahiyat - PRE
- John Kuch - CFO
- John Desjarlais - SVP
- Allen Yang - SVP
- Celia Eckert - VPR
- Jeremy Grunstein - VPR
- Eric Kowack - VPR
- Kirk Rosemark - VPR
- Julie Casciani - OTH
- A. Bruce Montgomery - LED
- Ellen Feigal - IND
- Kevin Gorman - IND
- Kurt Gustafson - IND
- Yujiro Hata - IND
- Richard Ranieri - IND
- Dagmar Rosa - Bjorkeson - IND